Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thais Warned on Drug Pricing Pressure (Thailand)

This article was originally published in PharmAsia News

Executive Summary

The European Commission has warned Thailand that if the nation forces drugmakers to drop prices for poor patients it will lose sales, adding to U.S. pressure over patent protection. Peter Mandelson, the EC trade commissioner, has written to Bangkok to protest against its consideration of a broad use of compulsory licenses, allowing it to import cheaper generic versions of branded medicines produced by western companies. Mandelson's letter says Bangkok "may be taking a new approach on access to medicines." The letter adds that "This approach is a matter of concern for the European Union and would be detrimental to the patent system, and so to innovation and the development of new medicines." Mandelson encouraged Bangkok to negotiate with Sanofi-Aventis, the Franco-German maker of Plavix, a drug for heart disease that has been supplanted by cheap Indian imports. Thailand has yet to reply to Brussels, but has denied these charges in the past. Mandelson's tough language may antagonize the European parliament. His letter was written in July just days before MEPs from all parties called on the EU to back more flexible compulsory licensing rules at the WTO. (Click here for more - May Require Paid Subscription

You may also be interested in...

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts